Literature DB >> 29131156

Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation.

F Farowski1,2, V Bücker1, J J Vehreschild1,2, L Biehl1,2, R Cruz-Aguilar1,2, C Scheid1, U Holtick1, N Jazmati2,3, H Wisplinghoff3, O A Cornely1,2,4,5, M J G T Vehreschild1,2.   

Abstract

Recent data link the incidence of intestinal GvHD (iGvHD) after allogeneic haematopoietic stem cell transplantation (aSCT) to exposure with piperacillin-tazobactam or imipenem-cilastatin. To assess relevance of timing, duration, sequence and combination of antibiotic treatment in this setting, we applied a time-dependent model to our aSCT cohort. Patients from the prospective Cologne Cohort of Neutropenic Patients (CoCoNut) undergoing aSCT from January 2007 to April 2013 were included into a time-dependent multivariate Cox proportional hazards regression model with backward-stepwise selection. In 399 eligible patients, cumulative antibiotic exposure (hazard ratio (HR) 2.46; 95% confidence interval (95% CI) 1.59-3.81; P<0.001) and exposure to sequential treatment with penicillin derivatives and carbapenems (HR 6.22, 95% CI 1.27-30.31), but not to the individual classes, were associated with iGvHD at day 100. Glycopeptides were assessed as a risk factor (HR 3.73, 95% CI 1.51-9.19), but not considered independent, since their use was dependent on previous exposure to penicillin derivatives and carbapenems. Patients with iGvHD presented with increased non-relapse mortality at day 365 (HR 3.51; 95% CI 2.10-5.89; P<0.001). We identified sequential exposure to penicillin derivatives and carbapenems as well as overall exposure to antibiotics as independent risk factors for iGVHD. Confirmation of these findings in larger, prospective cohorts is necessary.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29131156     DOI: 10.1038/bmt.2017.203

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation.

Authors:  Dayana Nasr; Mahmoudreza Moein; Stephanie Niforatos; Sandy Nasr; Mulham Ombada; Farzam Khokhar; Myera Shahnawaz; Bhavya Poudyal; Maroun Bou Zerdan; Dibyendu Dutta; Reza F Saidi; Seah H Lim
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

2.  Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Alex Ganetsky; Jennifer H Han; Mitchell E Hughes; Daria V Babushok; Noelle V Frey; Saar I Gill; Elizabeth O Hexner; Alison W Loren; Selina M Luger; James K Mangan; Mary Ellen Martin; Jacqueline Smith; Craig W Freyer; Cheryl Gilmar; Mindy Schuster; Edward A Stadtmauer; David L Porter
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

Review 3.  The role of microbiota in allogeneic hematopoietic stem cell transplantation.

Authors:  Chia-Chi Chang; Eiko Hayase; Robert R Jenq
Journal:  Expert Opin Biol Ther       Date:  2021-01-18       Impact factor: 5.589

Review 4.  Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation.

Authors:  Daniele Zama; Gianluca Bossù; Davide Leardini; Edoardo Muratore; Elena Biagi; Arcangelo Prete; Andrea Pession; Riccardo Masetti
Journal:  Ther Adv Hematol       Date:  2020-01-20

Review 5.  Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance.

Authors:  Tao Hong; Rui Wang; Xiaoqi Wang; Shijie Yang; Weihao Wang; Qiangguo Gao; Xi Zhang
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

Review 6.  Antibiotic Therapy and Gastrointestinal Graft-Versus-Host Disease in the Allogeneic Stem Cell Transplantation Population.

Authors:  Jessica Thomas; Christi Bowe; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.